Clinical Trial: A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07562022) titled 'A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma' on April 24.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Follicular Lymphoma (FL)

Intervention: DRUG: SCTB35 injection

SCTB35 will be subcutaneously administered at a dose as specified

DRUG: Rituximab

Intravenous Infusion

DRUG: Lenalidomide

Oral Capsules

Recruitment Stat...